bioMérieux – 2020 Financial Results
24 February, 2021
bioMérieux announces the CE marking of NEPHROCHECK® test on VIDAS®
03 February, 2021
Marcy l’Etoile, France – February 3rd , 2021 – bioMérieux, a world leader in the field of in vitro diagnostics, today announced the CE marking of the innovative NEPHROCHECK® assay to detect kidney stress in patients at risk of acute kidney injury (AKI).
bioMérieux announces the expansion of the CE marking of its molecular biology ARGENE® SARS-CoV-2 diagnostic test to include saliva specimens.
17 November, 2020
Marcy l’Etoile, France – November 16, 2020 – bioMérieux, a world leader in the field of in vitro diagnostics, has announced the expansion of its ARGENE® range for the detection of SARS-CoV-2. As a complement to nasopharyngeal swab specimens, the singleplex SARS-CoV-2 R-GENE® real-time PCR test may now be used on saliva and oropharyngeal (throat) swab specimens for the detection of the virus that causes COVID-19. This development helps optimize laboratory workflows.
First-Half 2020 Results
02 September, 2020
Second-Quarter 2020 Business Performance Preannouncement
15 July, 2020
bioMerieux CE Mark of VIDAS Serology test for SARS-COV-2
26 May, 2020
bioMérieux announces the CE marking of VIDAS® anti-SARS-CoV-2 serology tests to detect antibodies in people who have been exposed to SARS-CoV-2 which causes the COVID-19 disease. Read more here
COVID-19 Business Continuity
23 March, 2020
Information on business continuity for all our customers at the current time.